Blood, 141(21), 2657-2661. American Society of Hematology Ngai, L L, Hanekamp, D, Janssen, F, Carbaat-Ham, J, Hofland, M A M A, Fayed, M M H E, Kelder, A, Oudshoorn-van Marsbergen, L, Scholten, W J, Snel, A N, Bachas, C, Tettero, J M, Breems, D A, Fischer, T, Gjertsen, B T, Griškevičius, L, Juliusson, G, van de Loosdrecht, A A, Maertens, J A, Manz, M G, Pabst, T, Passweg, J R, Porkka, K, Valk, P J M, Gradowska, P, Löwenberg, B, de Leeuw, D C, Janssen, J J W M, Ossenkoppele, G J & Cloos, J 2023, ' Prospective validation of the prognostic relevance of CD34+CD38– AML stem cell frequency in the HOVON-SAKK132 trial ', Blood, vol. 141, no. 21, pp. 2657-2661 . https://doi.org/10.1182/blood.2022019160, https://doi.org/10.1182/blood.2022019160 Blood, 141, 21, pp. 2657-2661 Blood, 141, 2657-2661 Blood, Washington : Elsevier B.V., 2023, Early Access, p. [1-13]
Hilberink, Jacobien R; van Zeventer, Isabelle A; Chitu, Dana A; Pabst, Thomas; Klein, Saskia K; Stussi, Georg; Griskevicius, Laimonas; Valk, Peter J M; Cloos, Jacqueline; van de Loosdrecht, Arjan A; Breems, Dimitri; van Lammeren-Venema, Danielle; Boersma, Rinske; Jongen-Lavrencic, Mojca; Fehr, Martin; Hoogendoorn, Mels; Manz, Markus G; Söhne, Maaike; van Marwijk Kooy, Rien; Deeren, Dries; ... (2023). Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine. Blood cancer journal, 13(1), p. 93. Springer Nature 10.1038/s41408-023-00850-6